Stocks Health care CVRX
NASDAQ · Health careCVRx, Inc. (CVRX)
CVRx, Inc. brought in $61.2M of revenue over the twelve months to June 30, 2026, up 12.0% from a year earlier. It posted a net loss of $52M. In fiscal 2025 capital spending exceeded operating cash flow by $40.8M. At June 30, 2026 it held $64.6M in cash against $58.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about CVRx, Inc.
- Net worth
- CVRx, Inc. has a market value (market cap) of $20.8M at the latest share price, and shareholders' equity of $20M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $56.7M (+10.4% year on year), with a net loss of $53.3M. Over the 12 months to June 30, 2026: revenue $61.2M, net loss $52M.
- Cash flow
- In fiscal 2025 operations used $40.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- CVRx, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
What CVRx, Inc. does
CVRx, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker CVRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $56.7M | -$53.3M | -$2.04 | -$40.8M |
| 2024 | $51.3M | -$60M | -$2.65 | -$40.5M |
| 2023 | $39.3M | -$41.2M | -$1.99 | -$39.6M |
| 2022 | $22.5M | -$41.4M | -$2.02 | -$43.4M |
| 2021 | $13M | -$43.1M | -$4.16 | -$28.9M |
| 2021 | $6.1M | -$14.1M | -$37.01 | -$16.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CVRX ranks in Health care
Latest SEC filings
What CVRx, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 2, 2026Activist stake changed SCHEDULE 13D/A
- September 21, 2026Executive or director change8-KCVRx appointed John Landry as Chief Financial Officer to succeed Jared Oasheim.
- August 24, 2026Activist stake (5% or more) SCHEDULE 13D
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 16% to $15.7M versus the same quarter last year; diluted EPS -$0.53 versus -$0.57.
- August 6, 2026
- June 9, 2026
- June 3, 2026
- May 28, 2026
Insider trades
What the people running CVRx, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $76.4K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 13, 2026 | Binkowski BrentCHIEF OPERATING OFFICER | Bought | 26,223 | $76.4K |
| August 12, 2026 | Binkowski BrentCHIEF OPERATING OFFICER | Soldpre-planned (10b5-1) | 1,309 | $3.3K |
| June 1, 2026 | Dale Michael DDirector | Received as pay | 29,005 | - |
| June 1, 2026 | Slattery Joseph PDirector | Received as pay | 8,720 | - |
| June 1, 2026 | Nielsen Kirk G.Director | Received as pay | 8,720 | - |
| June 1, 2026 | Ballinger Kevin J.Director | Received as pay | 8,720 | - |
| June 1, 2026 | Jain Mudit K.Director | Received as pay | 8,720 | - |
| June 1, 2026 | Hill, Mitch C.Director | Received as pay | 8,720 | - |
Who owns CVRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| New Enterprise Associates 8A, Limited Partnership13D, may seek influence with 7 related filers | 9.3% | November 7, 2024 |
| New Enterprise Associates 10, Limited Partnership13D, may seek influence with 7 related filers | 7.8% | February 20, 2025 |
| Kirk Nielsen13G, passive with 3 related filers | 7.2% | February 6, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 88 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Johnson & Johnson | 4,024,861 | 0 |
| NEA Management Company, LLC | 1,954,440 | -71,643 |
| BlackRock, Inc. | 1,245,459 | +218,900 |
| Royal Bank of Canada | 1,233,212 | +526,262 |
| GSK plc | 1,007,583 | 0 |
| Vanguard Capital Management LLC | 910,576 | -734 |
| Silvercrest Asset Management Group LLC | 878,109 | +306,088 |
| Geode Capital Management, LLC | 440,786 | +13,714 |
| PFM Health Sciences, LP | 369,572 | new |
| State Street Corp | 366,352 | +15,804 |
| Renaissance Technologies LLC | 230,000 | +210,700 |
| UBS Group AG | 224,233 | +120,423 |
| Tudor Investment Corp ET AL | 205,684 | +8,344 |
| Goldman Sachs Group Inc | 149,509 | -51,502 |
| Morgan Stanley | 144,977 | +5,613 |
| Kestra Advisory Services, LLC | 132,400 | +84,500 |
| Two Sigma Investments, LP | 132,398 | +18,231 |
| Vanguard Fiduciary Trust Co | 128,955 | +1,194 |
| Dimensional Fund Advisors LP | 127,971 | +75,330 |
| Northern Trust Corp | 124,767 | -25,356 |
Insiders
14 insiders reported holding 1,777,422 shares in total, about $1.4M at the last price.
| Holder | Shares |
|---|---|
| Jain Mudit K.Director | 994,553980,183 held indirectly |
| Hykes KevinPRES & CEO, Director | 284,237 |
| Oasheim JaredCHIEF FINANCIAL OFFICER | 96,703 |
| John Robert AllenChief Revenue Officer | 86,036 |
| Adamson Philip B.Chief Medical Officer | 61,578 |
| Verrastro PaulCHIEF MKTG & STRAT OFFICER | 60,551 |
| Binkowski BrentCHIEF OPERATING OFFICER | 56,514 |
| Slattery Joseph PDirector | 39,365 |
| Morrison GregoryCHIEF HUMAN RESOURCES OFFICER | 34,000 |
| Dale Michael DDirector | 29,005 |
Questions about CVRX
What does CVRx, Inc. do?
CVRx, Inc. is a company in the Health care sector, listed on NASDAQ as CVRX. Its shares trade on NASDAQ under the ticker CVRX.
What is CVRx, Inc.'s net worth?
CVRx, Inc. has a market value (market cap) of $20.8M at the latest share price, and shareholders' equity of $20M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is CVRx, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $52M on revenue of $61.2M.
How much revenue does CVRx, Inc. make?
Over the twelve months to June 30, 2026 CVRx, Inc. reported revenue of $61.2M. That is 12.0% more than a year earlier.
When did CVRx, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from October 2, 2026.
When is CVRx, Inc.'s next earnings report?
CVRx, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
Similar companies
Compare CVRX with
Follow CVRX
Get an email when CVRx, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values CVRx, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.